Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Pirtobrutinib in Previously Treated Waldenström Macroglobulinemia
NCT05734495Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2023
- Primary completion
- Jan 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pirtobrutinib, venetoclax in Waldenstrom macroglobulinemia (WM), sponsored by Dana-Farber Cancer Institute. Started May 2023; status: active, not recruiting.
02
Drugs
pirtobrutinibvenetoclax
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT05734495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05734495.